Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096694 · ClinicalTrials.gov registry record · NA
Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 41
- Enrollment target
NCT00096694: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00096694 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 41 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096694, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 41 participants
- Enrollment target
Study Summary
Oral contraceptives (OCs) are not a good option for some HIV infected women because of the potential for drug interactions between OCs and anti-HIV drugs; additionally, OCs may increase the risk of transmitting HIV to sexual partners. Levonorgestrel is commonly prescribed as part of a combination OC. An intrauterine device (IUD) is a device inserted in a woman's uterus to prevent pregnancy. The purpose of this study is to determine the effect of a levonorgestrel-releasing IUD on the amount of HIV present in an HIV infected woman's cervix after 4 weeks of IUD use. Study hypothesis: There will be no increase in genital tract HIV RNA and DNA after placement of the levonorgestrel IUD.
Interventions
- DEVICE Levonorgestrel-releasing intrauterine device (IUD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Est. Completion | 2005-09 |
| Phase | NA |
What the finished NCT00096694 record still lists
NCT00096694 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Levonorgestrel-releasing intrauterine device (IUD) is the first listed.
NCT00096694 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096694 about?
NCT00096694 is a clinical study titled "Effect of an Intrauterine Contraceptive Device (IUD) in HIV Infected Women". Oral contraceptives (OCs) are not a good option for some HIV infected women because of the potential for drug interactions between OCs and anti-HIV drugs; additionally, OCs may increase the risk of transmitting HIV to sexual partners. Levonorgestrel is commonly prescribed as part of a combination OC...
What is the current status of trial NCT00096694?
This trial is currently completed. It is a NA study. The enrollment target is 41 participants. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00096694?
The interventions under investigation include: Levonorgestrel-releasing intrauterine device (IUD) (DEVICE).
Who is sponsoring clinical trial NCT00096694?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00096694's enrollment target sits among peer trials
41 1446th of 2000 higher than 554 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS